Skip to main content
NewslettersWatchlist

Oncolytics Bio(ONC-T)
TSX

Today's Change
Real-Time Last Update
Day Low1.32
Day High1.39
Open:1.39
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
BayStreet.ca
Biotech Companies’ Q3 Updates: Promising Cancer Treatments on the Horizon
Newswire.ca
Biotech Companies' Q3 Updates: Promising Cancer Treatments on the Horizon
Baystreet
Stocks in play: Oncolytics Biotech Inc
Baystreet
Stocks in play: Oncolytics Biotech® Inc.
Newswire.ca
Oncolytics Biotech® Reports Third Quarter 2024 Financial Results and Operational Highlights
Baystreet
Stocks in play: Oncolytics Biotech Inc
Baystreet
Stocks in play: Oncolytics Biotech® Inc.
Newswire.ca
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
BayStreet.ca
Biotech Advances Gain Momentum Amid October’s Rising Breast Cancer Rates and Awareness Efforts
Newswire.ca
Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women
Baystreet
Stocks in play: Oncolytics Biotech® Inc.
BayStreet.ca
FDA Oncology Approvals Accelerate as Global Cancer Rates Set to Climb 77%
Newswire.ca
FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
Baystreet
Stocks in play: Oncolytics Biotech Inc
Newswire.ca
Oncolytics Biotech® Announces Key Progress and Upcoming Studies for Breast and Pancreatic Cancer Treatments, Prepares for FDA Accelerated Approval Path
BayStreet.ca
Promising Progress in Oncology as Cancer Deaths Decline and Research Grows
Newswire.ca
Optimism Grows in the Fight Against Cancer as Breakthroughs and Funding Increase
Newswire.ca
Global Cancer Rates Surge as Biotech Innovators Work on New Therapies
BayStreet.ca
Investors Watch Key Players in Oncology as Cancer Cases Set to Skyrocket
GlobeNewswire
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
Newswire.ca
Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players
BayStreet.ca
Recent Breakthroughs in Cancer Research Could Impact These Key Companies

Profile

Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.